Retinal Biologics Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Retinal Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (VEGF-A Antagonist, Others), By Indication (Macular Degeneration, Diabetic Retinopathy, Others), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Retinal Biologics Market is projected to expand from USD 16.18 billion in 2025 to USD 21.18 billion by 2031, reflecting a compound annual growth rate of 4.59%. These biological treatments, primarily vascular endothelial growth factor inhibitors delivered via intravitreal injection, are essential for managing progressive eye conditions such as age-related macular degeneration and diabetic macular edema. The sector's growth is largely driven by an aging global population and rising rates of diabetes, creating a critical need for long-term therapies to prevent vision loss from retinal complications.
High treatment costs and the discomfort of frequent eye injections pose significant hurdles to market development, often resulting in patient noncompliance. Despite these challenges, the demand for effective therapies persists due to the growing global burden of ocular diseases. According to the International Agency for the Prevention of Blindness in 2025, the number of people suffering from sight loss is expected to reach 1.8 billion by 2050. This forecast highlights the urgent requirement for scalable therapeutic solutions within the retinal biologics landscape.
Market Driver
The rising global incidence of diabetes and its associated complications serves as a fundamental catalyst for the retinal biologics industry. As systemic metabolic disorders become more common, the consequent increase in diabetic macular edema and diabetic retinopathy requires continuous pharmacologic treatment to avert permanent blindness. This demographic trend creates essential demand for intravitreal therapies, with the International Diabetes Federation’s 2025 'IDF Diabetes Atlas 11th Edition' reporting that 11.1% of the global adult population now lives with diabetes. This vast patient pool necessitates sustained volume growth in the market as healthcare providers rely on standard anti-VEGF treatments to manage these chronic threats to vision.
Concurrently, the competitive landscape is being transformed by advancements in novel gene therapies and long-acting biologics that address the heavy burden of frequent treatments. Patients and physicians are increasingly adopting next-generation bispecific antibodies and high-dose formulations that permit longer intervals between doses, thereby enhancing compliance and outcomes. For instance, Roche’s '2024 Annual Report' from January 2025 noted that the bispecific antibody Vabysmo achieved full-year sales of CHF 3.9 billion, while Regeneron’s 'Third Quarter 2024 Financial Results' in October 2024 reported Eylea HD generated $392 million in U.S. net sales for that quarter alone. These figures confirm the sector's decisive shift toward durable therapeutics that offer reduced injection frequency.
Market Challenge
The major obstacle constraining the Global Retinal Biologics Market is the high cost of medication coupled with the substantial burden of frequent intravitreal injections. Because these biological agents require repeated administration to preserve sight, they impose a compounding financial and logistical weight on patients and healthcare infrastructures alike. Consequently, many individuals face treatment fatigue or unmanageable out-of-pocket costs, resulting in poor adherence, missed appointments, or total therapy cessation. This pattern of noncompliance directly diminishes the addressable patient base and restricts the long-term revenue opportunities for approved branded biologics.
Furthermore, the economic strain of these recurring expenses compels clinical practices to modify prescribing habits, often negatively impacting market value. When financial safety nets are exhausted, physicians are frequently forced to transition patients from premium, first-line branded therapies to less expensive, off-label alternatives to maintain some level of care. According to the American Society of Retina Specialists in 2025, 93 percent of surveyed retina specialists indicated they switched patients to lower-cost options following the depletion of charitable copay assistance funds. This significant migration away from premium treatments erodes the market share of approved biologics and underscores the vulnerability of growth that relies on subsidized patient access.
Market Trends
The rapid commercialization of anti-VEGF biosimilars is fundamentally reshaping market dynamics by challenging the dominance of legacy brands and introducing cost-efficient competition. As patents for key reference biologics expire, major pharmaceutical companies are actively launching biosimilar alternatives that provide comparable clinical efficacy at lower prices, thereby widening patient access and driving price reductions across the industry. This trend is illustrated by the swift uptake of newly approved aflibercept biosimilars; for example, Amgen’s 'Q1 2025 Earnings Call' in May 2025 reported that their biosimilar Pavblu achieved $99 million in quarterly sales, signaling strong adoption by payers and retinal specialists.
Simultaneously, the rise of complement inhibitors for Geographic Atrophy marks a pivotal expansion from managing wet age-related macular degeneration to treating previously untreatable dry forms of the condition. This novel therapeutic class targets the complement cascade to retard lesion progression, effectively unlocking a significant market segment defined by high unmet medical needs. The successful adoption of these pioneering therapies highlights the critical demand for treatments that preserve vision in advanced non-neovascular disease. According to Apellis Pharmaceuticals’ 'Q3 2025 Financial Results' from October 2025, the complement inhibitor Syfovre recorded net product revenue of $150.9 million for the quarter, validating the commercial potential of therapeutics addressing this broad patient population.
Key Market Players
* AbbVie Inc.
* Amgen Inc.
* Bayer AG
* Biocon Limited
* Biogen Inc.
* Coherus BioSciences, Inc.
* F. Hoffmann-La Roche Ltd.
* Novartis AG
* Outlook Therapeutics, Inc.
* Regeneron Pharmaceuticals, Inc.
Report Scope
In this report, the Global Retinal Biologics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Retinal Biologics Market, By Drug Class
* VEGF-A Antagonist
* Others
# Retinal Biologics Market, By Indication
* Macular Degeneration
* Diabetic Retinopathy
* Others
# Retinal Biologics Market, By Distribution Channel
* Hospital Pharmacies
* Online Providers
* Drug Stores
* Retail Pharmacies
# Retinal Biologics Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Retinal Biologics Market.
Available Customizations:
Global Retinal Biologics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Retinal Biologics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (VEGF-A Antagonist, Others)
5.2.2. By Indication (Macular Degeneration, Diabetic Retinopathy, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores, Retail Pharmacies)
5.2.4. By Region
5.2.5. By Company (2025)
5.3. Market Map
6. North America Retinal Biologics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Indication
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Retinal Biologics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Indication
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Retinal Biologics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Indication
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Retinal Biologics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Indication
6.3.3.2.3. By Distribution Channel
7. Europe Retinal Biologics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Indication
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Retinal Biologics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Indication
7.3.1.2.3. By Distribution Channel
7.3.2. France Retinal Biologics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Indication
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Retinal Biologics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Indication
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Retinal Biologics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Indication
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Retinal Biologics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Indication
7.3.5.2.3. By Distribution Channel
8. Asia Pacific Retinal Biologics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Indication
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Retinal Biologics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Indication
8.3.1.2.3. By Distribution Channel
8.3.2. India Retinal Biologics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Indication
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Retinal Biologics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Indication
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Retinal Biologics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Indication
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Retinal Biologics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Indication
8.3.5.2.3. By Distribution Channel
9. Middle East & Africa Retinal Biologics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Retinal Biologics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Indication
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Retinal Biologics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Indication
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Retinal Biologics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Indication
9.3.3.2.3. By Distribution Channel
10. South America Retinal Biologics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Retinal Biologics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Indication
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Retinal Biologics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Indication
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Retinal Biologics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Indication
10.3.3.2.3. By Distribution Channel
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Retinal Biologics Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. AbbVie Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Amgen Inc.
15.3. Bayer AG
15.4. Biocon Limited
15.5. Biogen Inc.
15.6. Coherus BioSciences, Inc.
15.7. F. Hoffmann-La Roche Ltd.
15.8. Novartis AG
15.9. Outlook Therapeutics, Inc.
15.10. Regeneron Pharmaceuticals, Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們